HLS Therapeutics (HLS) Stock Price, News & Analysis

Company Overview

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Key Stats

• Today's Range: C$3.45 to C$3.74
• 50-Day Range: C$3.13 to C$3.99
• 52-Week Range: C$3.00 to C$5.48
• Volume: 626,653 shs
• Average Volume: 31,135 shs
• Market Capitalization: C$115.08 million
• P/E Ratio: N/A
• Dividend Yield: 5.52%
• Price Target: C$4.13
• Consensus Rating: Buy

HLS Therapeutics Stock Analysis - MarketRank™

HLS Therapeutics scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

HLS Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

HLS Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of HLS Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HLS Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HLS Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HLS.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

HLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

HLS Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HLS.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.81

News Sentiment

HLS Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for HLS Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, HLS Therapeutics insiders have bought 312.39% more of their company's stock than they have sold. Specifically, they have bought C$6,825.00 in company stock and sold C$1,655.00 in company stock.

Percentage Held by Insiders

Only 0.37% of the stock of HLS Therapeutics is held by insiders.

Percentage Held by Institutions

65.20% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HLS Stock Analysis - Frequently Asked Questions

How have HLS shares performed this year?

HLS Therapeutics' stock was trading at C$3.95 on January 1st, 2024. Since then, HLS stock has decreased by 8.4% and is now trading at C$3.62.
View the best growth stocks for 2024 here.

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.22. The business had revenue of $22.05 million for the quarter, compared to the consensus estimate of $21.17 million. HLS Therapeutics had a negative net margin of 40.90% and a negative trailing twelve-month return on equity of 24.82%.

How do I buy shares of HLS Therapeutics?

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV).

Company Calendar

• Last Earnings: 8/10/2023
• Today: 12/18/2024

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:HLS
• CUSIP: N/A
• CIK: N/A
• Web: www.hlstherapeutics.com
• Phone: 647-495-9000
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$4.13
• High Stock Price Target: C$5.00
• Low Stock Price Target: C$3.25
• Potential Upside/Downside: +14.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($1.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-24,090,000.00
• Net Margins: -40.90%
• Pretax Margin: N/A
• Return on Equity: -24.82%
• Return on Assets: -2.89%

Debt

• Debt-to-Equity Ratio: 100.44
• Current Ratio: 2.02
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: C$58.89 million
• Price / Sales: 1.95
• Cash Flow: C$0.24 per share
• Price / Cash Flow: 15.22
• Book Value: C$2.60 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 31,790,000
• Free Float: N/A
• Market Cap: C$115.08 million
• Optionable: Not Optionable
• Beta: 1.07